DrugPatentWatch Database Preview
Drugs in Development Information for Ibudilast
» See Plans and Pricing
What is the development status for investigational drug Ibudilast?
Ibudilast is an investigational drug.
There have been 19 clinical trials for Ibudilast.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2020.
The most common disease conditions in clinical trials are Sclerosis, Motor Neuron Disease, and Amyotrophic Lateral Sclerosis. The leading clinical trial sponsors are MediciNova, University of California, Los Angeles, and National Institute on Drug Abuse (NIDA).
There are seven hundred and thirty-six US patents protecting this investigational drug and seven international patents.
Summary for Ibudilast
| US Patents | 736 |
| International Patents | 7,426 |
| US Patent Applications | 1,657 |
| WIPO Patent Applications | 2,044 |
| Japanese Patent Applications | 12 |
| Clinical Trial Progress | Phase 2 (2020-12-01) |
| Vendors | 88 |
Recent Clinical Trials for Ibudilast
| Title | Sponsor | Phase |
|---|---|---|
| Regeneration in Cervical Degenerative Myelopathy | Cambridge University Hospitals NHS Foundation Trust | Phase 3 |
| Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS | MediciNova | Phase 2 |
| Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | MediciNova | Phase 2/Phase 3 |
Clinical Trial Summary for Ibudilast
Top disease conditions for Ibudilast
Top clinical trial sponsors for Ibudilast
US Patents for Ibudilast
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ibudilast | Start Trial | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| Ibudilast | Start Trial | Therapeutic approaches for treating Parkinson's disease | Pharnext (Issy les Moulineaux, FR) | Start Trial |
| Ibudilast | Start Trial | Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells | Selecta Biosciences, Inc. (Watertown, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ibudilast
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ibudilast | Canada | CA2961033 | 2034-09-11 | Start Trial |
| Ibudilast | European Patent Office | EP3192791 | 2034-09-11 | Start Trial |
| Ibudilast | Japan | JPWO2016039408 | 2034-09-11 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
